AAIC 2025 Abstract·23 DecCorrelations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in the Pre‐Specified MCI Group: Subgroup Analysis from the 78‐Week APOLLOE4 Phase 3 Trial in APOE4/4 HomozygotesTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecEfficacy and Safety of Oral Valiltramiprosate in APOE4/4 Homozygotes with Early AD: Topline Results from the APOLLOE4 Phase 3 TrialTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecValiltramiprosate Effects on Microstructural Integrity of Grey and White Matter in APOE4/4 Homozygotes with Early AD and their Correlations to Clinical Outcomes: MRI Mean Diffusivity Results from the 78‐Week APOLLOE4 Phase 3 TrialTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecSafety and ARIA Results of the Oral Anti‐Amyloid Agent Valiltramiprosate from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early ADTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecValiltramiprosate/ALZ‐801 Prevents Hippocampal Atrophy and Clinical Decline in a Stage 2 AD Subpopulation in APOLLOE4 Phase 3 StudyTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecQuantitative System Pharmacology Analysis of Oral Valiltramiprosate/ALZ‐801 Predicts Slowing of Alzheimer’s Disease Progression by Anti‐Amyloid Oligomer and APOE4 Structural Corrector Modes of ActionComputational studyInterventionsPaper
AAIC 2025 Abstract·23 DecQuantitative Systems Pharmacology Analysis of Hippocampal Volume Trajectory by APOE Genotype and Neuroprotective Effects of Valiltramiprosate/ALZ‐801 in Early ADComputational studyInterventionsPaper